论文部分内容阅读
Ｇｉｌｅａｄ开始ＧＳ－５０４的第二次Ⅱ／Ⅲ期临床试验奇利得（Ｇｉｌｅａｄ）公司已开始对核苷酸类似物ＧＳ—５０４进行第二次Ⅱ／Ⅲ临床试验，对象是９０名患有与巨细胞病毒视网膜炎有关的艾滋病人。１９９４年１月的第－次Ⅱ／Ⅲ期试验是对在美国、英国（见Ｓｃｒｉ...
Gilead Launches Second Phase II / III GS-504 Clinical Trial Gilead Corporation has begun a second Phase II / III clinical trial of nucleotide analogue GS-504 targeting 90 patients with and without giant Cytomegalovirus Retinitis Associated with AIDS. January 1994 - the first Ⅱ / Ⅲ trial is in the United States, Britain (see Scri ...